CannTrust Holdings Inc (TSX: TRST)(NYSE: CTST) has named Dr Len Walt, MD, MBA as its new chief medical officer, it was reported yesterday.
Dr Walt will lead the global medical function dedicated to strengthening the company's clinical research strategy, medical education programs, product innovation and support the expansion of CannTrust's global medical businesses and partnerships.
Dr Walt comes to CannTrust with extensive senior leadership experience in the pharmaceutical and biotechnology industries in Canada, USA and abroad. Most recently he held the position of vice president and head of Medical Affairs at Sobi Inc, where he led the company's North American medical and scientific operations. Previously, he held the position of medical director at Biogen Canada, where he built medical teams and developed relationships with key clinical investigators in Canada.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study